Details

Autor(en) / Beteiligte

• Feola, Tiziana
• Centello, Roberta
• Sesti, Franz
• Puliani, Giulia
• Verrico, Monica
• Di Vito, Valentina
• Di Gioia, Cira
• Bagni, Oreste
• Lenzi, Andrea
• Isidori, Andrea M
• Giannetta, Elisa
• Faggiano, Antongiulio

Titel

Neuroendocrine Carcinomas with Atypical Proliferation Index and Clinical Behavior: A Systematic Review

Ist Teil von

• Cancers, 2021-03, Vol.13 (6), p.1247

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2021

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Highly proliferative (G3) neuroendocrine neoplasms are divided into well differentiated tumors (NETs) and poorly differentiated carcinomas (NECs), based on the morphological appearance. This systematic review aims to evaluate the clinicopathological features and the treatment response of the NEC subgroup with a Ki67 labeling index (LI) < 55%. A literature search was performed using MEDLINE, Cochrane Library, and Scopus between December 2019 and April 2020, last update in October 2020. We included studies reporting data on the clinicopathological characteristics, survival, and/or therapy efficacy of patients with NECs, in which the Ki67 LI was specified. 8 papers were included, on a total of 268 NEC affected patients. NECs with a Ki67 LI < 55% have been reported in patients of both sexes, mainly of sixth decade, pancreatic origin, and large-cell morphology. The prevalent treatment choice was chemotherapy, followed by surgery and, in only one study, peptide receptor radionuclide therapy. The subgroup of patients with NEC with a Ki67 LI < 55% showed longer overall survival and progression free survival and higher response rates than the subgroup of patients with a tumor with higher Ki67 LI (≥55%). NECs are heterogeneous tumors. The subgroup with a Ki67 LI < 55% has a better prognosis and should be treated and monitored differently from NECs with a Ki67 LI ≥ 55%.